Am J Transplant, Volume 5, Suppl 3 Archives - Page 121 of 170 - ATC Abstracts

2015 American Transplant Congress
A Relative Survival Model to Compare the Risk of Mortality in Patients Awaiting Kidney Transplantation Versus Already Transplanted Patients
M. Lorent,^1,2 K. Trébern-Launay,^2,1 C. Legendre,⁴ H. Kreis,⁴ G. Mourad,⁵ V. Garrigue,⁵ L. Rostaing,⁶ N. Kamar,⁶ M. Kessler,⁷ M. Ladrière,⁷ E. Morelon,⁸ F. Buron,⁸ M. Giral,^2,3 Y. Foucher.^1,2
¹EA 4275 - SPHERE bioStatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France; ²Institut de Transplantation, Urologie, Néphrologie (ITUN), Inserm U1064, CHU de Nantes, Nantes, France; ³CIC Biotherapy, CHU Nantes, Nantes, France; ⁴Service de Transplantation Rénale et de Soins Intensifs, Hôpital Necker, APHP Paris, Paris, France; ⁵Service de Néphrologie-Transplantation, Hôpital Lapeyronie, Montpellier, France; ⁶Service de Néphrologie, HTA, Dialyse et Transplantation d'Organes, CHU Rangueil, Toulouse, France; ⁷Service de Transplantation Rénale, CHU Brabois, Nancy, France; ⁸Service de Néphrologie, Transplantation et Immunologie Clinique, Hôpital Edouard Herriot, Lyon, France.
Introduction: It would be useful for physicians in some specific cases to identify whom patients could not benefit of kidney transplantations.Patients and method: To answer…
2015 American Transplant Congress
Is Organ Transplantation from Trypanosoma cruzi-Infected Donors Safe? An Autopsy-Based Study of Parasite Persistence in Chronic Chagasic Patients
L. Benvenuti, A. Roggério.
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Introduction: Chagas' disease, endemic in Latin America, is caused by infection with the protozoan Trypanosoma cruzi. The disease can affect the heart and/or the gastrointestinal…
2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
J. Kahwaji,¹ S. Louie,¹ A. Vo,¹ J. Choi,¹ M. Toyoda,² S. Ge,² P. Wongsaroj,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…
2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
P. Wongsaroj,¹ J. Choi,¹ A. Vo,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ M. Haas,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…
2015 American Transplant Congress
De Novo Donor-Specific HLA Antibodies After Kidney Transplantation Are Associated With Donation After Circulatory Death and HLA-DQ Mismatch
G. Dreyer,¹ D. Roelen,² S. Brand-Schaaf,² O. Dekkers,³ M. Reinders,¹ F. Claas,² J. de Fijter.¹
¹Nephrologie, LUMC, Leiden, Netherlands; ²Immunohaematology and Blood Transfusion, LUMC, Leiden, Netherlands; ³Clinical Epidemiology, Aarhus Medical Center, Aarhus C, Denmark.
Introduction: De novo donor-specific HLA-antibodies (dnDSA) have been associated with rejection and inferior kidney graft survival. The purpose of this study was to investigate the…
2015 American Transplant Congress
Association of De Novo Antibody-Mediated Rejection and Increased Hospital Costs Following Kidney Transplant in Immunologically Low-Risk Patients
S. Kulkarni,¹ I. Hall.²
¹Section of Organ Transplantation & Immunology, Yale University, New Haven, CT; ²Section of Nephrology, Yale University, New Haven, CT.
While antibody-mediated rejection (AMR) is likely the primary cause of kidney transplant (KTx) failure, and its treatment can be considered expensive, incremental center costs for…
2015 American Transplant Congress
High Mortality in Diabetic Recipients of High KDPI Deceased Donor Kidneys
R. Pelletier,¹ T. Pesavento,² A. Rajab,¹ M. Henry.¹
¹Surgery/Transplant, The Ohio State University Medical Center, Columbus, OH; ²Transplant Nephrology, The Ohio State University Medical Center, Columbus, OH.
Deceased donor (DD) kidney quality is determined using the Kidney Donor Profile Index (KDPI). How best to allocate the high KDPI kidneys (KDPI ≥ 85%)…
2015 American Transplant Congress
A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients
M. Janusek,¹ S. Patel,² K. Galen,¹ P. West-Thilke,¹ E. Benedetti,¹ J. Thielke.¹
¹University of Illinois Hospital and Health Sciences System, Chicago, IL; ²VA Great Lakes Health Care System, Westchester, IL.
Background:Greater than 90% of all kidney transplants(KTx) today receive an induction agent. The choice of a depleting or non-depleting agent is center specific. Alemtuzumab (Alem),…
2015 American Transplant Congress
The Role of Immunosuppression on Cardiac Functions of Kidney Transplant Recipients
U. Cakir, O. Cavdaroglu, T. Erturk, E. Gurluler, A. Gurkan, I. Berber.
Transplant Center, Acibadem University, Istanbul, Turkey.
Cardiac disorders are associated with high morbidity and mortality in end-stage renal disease (ESRD).Kidney transplantation is known to increase the survival of dialysis patients by…
2015 American Transplant Congress
HCV Treatment in Liver Transplantation: Changes in Center Attitudes and Practices in the DAA Era
A. Shaffer, A. Cash, S. Anjum, D. Segev, C. Durand.
Surgery, Johns Hopkins University, Baltimore, MD.
Chronic hepatitis C virus infection (HCV) is the leading indication for liver transplantation (LT) in the US. Safe and effective directly acting antivirals (DAAs) are…